First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis - Emens, Leisha Ann; Adams, S.; Barrios, C. H.; Diéras, V.; Iwata, H.; Loi, S.; Rugo, H. S.; Schneeweiss, Andreas; Winer, E. P.; Patel, S.; Henschel, V.; Swat, A.; et al. (Annals of oncology, 2021)
Gesehen am 02.11.2021